Drug Trial Radar · NCT06386419
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Nov 12, 2024
Primary completion
Jan 13, 2026
Study completion Jan 13, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to generate post-marketing safety and effectiveness data of inclisiran sodium in Indian patients as per approved indication i.e., primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia that more closely resembles the real-world population intended to be treated with inclisiran sodium.
Conditions
- Primary Hypercholesterolemia
- Mixed Dyslipidemia
Interventions
inclisiranDrug
Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and type of treatment-emergent adverse events (TEAEs)Time frame: 10 months (300 days)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Belagavi, Karnataka, India
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Novartis Investigative Site
Madurai, Tamil Nadu, India
Novartis Investigative Site
Vellore, Tamil Nadu, India
Novartis Investigative Site
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.